|
Synonyms: BOS 161721 | BOS161721
Compound class:
Antibody
Comment: Avizakimab (BOS161721; Boston Pharmaceuticals) is a humanized anti-IL-21 antibody that inhibits IL-21 bioactivity. It was developed for potential to treat systemic lupus erythematosus (SLE), an auotimmune condition in which IL-21 is implicated as a driving factor [3-5]. IL-21 has been explored as a therapeutic target in a range of autoimmune disease models (SLE, rheumatoid arthritis, type 1 diabetes and psoriasis). Peptide sequences for avizakimab are claimed in Boston Pharmaceuticals' patent US10022443B2 [1].
|
| No information available. |
Summary of Clinical Use  |
| Avizakimab (BOS161721) has been advanced as a clinical lead. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT03371251 | Study of BOS161721 in Systemic Lupus Erythematosus (SLE) Patients on a Background of Limited Standard of Care | Phase 1/Phase 2 Interventional | Boston Pharmaceuticals | ||
| NCT03036865 | Study to Assess the Safety, Pharmacokinetics and Pharmacodynamics of BOS161721 in Healthy Subjects | Phase 1 Interventional | Boston Pharmaceuticals | Safety, tolerability, target engagement and pharmacological activity were demonstrated in this Phase 1 study. | 2 |
